Related Experiment Video
Updated: Nov 4, 2025

09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.8K
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
Alyxzandria M Gaydosik1, Tracy Tabib1, Robyn Domsic1
1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Annals of the Rheumatic Diseases
|May 25, 2021
Summary
Researchers identified a unique T cell subset in systemic sclerosis (SSc) skin that may drive disease progression. This finding could lead to targeted therapies for SSc, improving patient outcomes and reducing treatment toxicity.
Area of Science:
- Immunology
- Dermatology
- Genomics
Background:
- T cells are implicated in systemic sclerosis (SSc) pathogenesis.
- Comprehensive studies on T-cell responses in SSc skin are limited.
- Understanding T-cell heterogeneity is crucial for SSc research.
Purpose of the Study:
- To investigate T-cell-mediated immune responses in progressive SSc skin.
- To analyze patient-specific T-cell heterogeneity using single-cell transcriptomics.
- To identify novel gene expression related to SSc severity.
Main Methods:
- Droplet-based single-cell RNA sequencing of 3729 CD3+ lymphocytes from SSc and healthy skin biopsies.
- Analysis of samples from 27 SSc patients and 10 healthy donors.
- Validation using confocal immunofluorescence microscopy.
Main Results:
- Identified distinct recirculating and tissue-resident T cell subsets in healthy and SSc skin.
- Discovered a unique cluster of CXCL13+ T cells in SSc skin with a T helper follicular-like signature.
- Observed that these T cells may promote B-cell responses in inflamed SSc skin.
Conclusions:
- Current SSc therapies cause broad immune cell toxicity.
- Targeting specific immune mechanisms in SSc can lead to more effective and less toxic treatments.
- This study provides a basis for developing novel, targeted SSc therapies.

